光线性角化病恶性进展相关生物标志物的研究进展

doi:10.35541/cjd.20220284

中华皮肤科杂志 ›› 2023, e20220284.doi: 10.35541/cjd.20220284

光线性角化病恶性进展相关生物标志物的研究进展

何庆¹ 张涛² 王秀丽³ 高兴华¹ 陈洪铎¹ 柳敏^1，4 齐瑞群¹

¹中国医科大学附属第一医院皮肤科国家卫生健康委员会免疫皮肤病学重点实验室免疫皮肤病学教育部重点实验室免疫性皮肤病诊疗技术国家地方联合工程研究中心，沈阳 110001；²中国医科大学干细胞与再生医学研究室，沈阳 110001；³上海市皮肤病医院皮肤科，上海 200443；⁴中国医科大学呼吸疾病研究所，沈阳 110001

收稿日期:2022-04-22 修回日期:2023-02-03 发布日期:2023-12-05
通讯作者: 齐瑞群；柳敏 E-mail:xiaoqiliumin@163.com; liuminxiaoqi@163.com
基金资助:
国家自然科学基金（82173401、81673070、U1908206）

Biomarkers associated with malignant progression of actinic keratosis

He Qing¹, Zhang Tao², Wang Xiuli³, Gao Xinghua¹, Chen Hongduo¹, Liu Min^1,4, Qi Ruiqun¹

¹Department of Dermatology, The First Affiliated Hospital of China Medical University, NHC Key Laboratory of Immunodermatology （China Medical University）, Key Laboratory of Immunodermatology （China Medical University）, Ministry of Education, National and Local Joint Engineering Research Center of Immunodermatological Theranostics, Shenyang 110001, China; ²Department of Stem Cells and Regenerative Medicine, China Medical University, Shenyang 110001, China; ³Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai 200443, China; ⁴Institute of Respiratory Disease, China Medical University, Shenyang 110001, China

Received:2022-04-22 Revised:2023-02-03 Published:2023-12-05
Contact: Qi Ruiqun; Liu Min E-mail:xiaoqiliumin@163.com; liuminxiaoqi@163.com
Supported by:
National Natural Science Foundation of China（82173401、81673070、U1908206）

摘要/Abstract

摘要： 【摘要】光线性角化病是日光长期暴露引起的一种癌前病变，可发展为皮肤鳞状细胞癌。鲍恩病是一种表皮内鳞状细胞癌。光线性角化病、鲍恩病和皮肤鳞状细胞癌的鉴别诊断及皮肤鳞状细胞癌的早期诊断一直是研究热点。本文综述光线性角化病恶性进展相关的生物标志物，以期为临床早期诊断提供参考。

关键词: 角化病, 光化性, 癌, 鳞状细胞, Bowen病, 生物标记, 肿瘤, 细胞转化, 肿瘤, 鉴别诊断

Abstract: 【Abstract】 Actinic keratosis is a precancerous skin lesion caused by long-term sun exposure, and may progress to cutaneous squamous cell carcinoma. Bowen′s disease is an in-situ squamous cell carcinoma of the epidermis. Differential diagnosis of actinic keratosis, Bowen′s disease and cutaneous squamous cell carcinoma, as well as early diagnosis of cutaneous squamous cell carcinoma, have always been research hotspots. This review summarizes biomarkers related to the malignant progression of actinic keratosis, with a view to providing a reference for early clinical diagnosis.

Key words: Keratosis, actinic, Carcinoma, squamous cell, Bowen′s disease, Biomarkers, tumor, Cell transformation, neoplastic, Differential diagnosis

何庆张涛王秀丽高兴华陈洪铎柳敏, 齐瑞群. 光线性角化病恶性进展相关生物标志物的研究进展[J]. 中华皮肤科杂志, 2023,e20220284. doi:10.35541/cjd.20220284

He Qing, Zhang Tao, Wang Xiuli, Gao Xinghua, Chen Hongduo, Liu Min, Qi Ruiqun. Biomarkers associated with malignant progression of actinic keratosis[J]. Chinese Journal of Dermatology,2023,e20220284. doi:10.35541/cjd.20220284

参考文献 47

［1］	中国康复医学会皮肤病康复专业委员会, 中华医学会皮肤性病学分会光动力治疗研究中心, 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 中国光线性角化病临床诊疗专家共识（2021）［J］. 中华皮肤科杂志, 2021,54（12）:1048⁃1056. doi: 10.35541/cjd.20210561.
［2］	Flohil SC, van der Leest RJ, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam study［J］. J Invest Dermatol, 2013,133（8）:1971⁃1978. doi: 10.1038/jid.2013.134.
［3］	Fargnoli MC, Altomare G, Benati E, et al. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics［J］. Eur J Dermatol, 2017,27（6）:599⁃608. doi: 10.1684/ejd.2017.3126.
［4］	Xu D, Sun JF, Qi RQ, et al. A multicenter retrospective analysis of the clinical and pathological characteristics of 1 188 cases of actinic keratosis in different ultraviolet radiation intensity areas of China［J］. J Cosmet Dermatol, 2022,21（7）:2879⁃2888. doi: 10.1111/jocd.14479.
［5］	Ratushny V, Gober MD, Hick R, et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma［J］. J Clin Invest, 2012,122（2）:464⁃472. doi: 10.1172/JCI57415.
［6］	Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans affairs topical tretinoin chemoprevention trial［J］. Cancer, 2009,115（11）:2523⁃2530. doi: 10.1002/cncr.24284.
［7］	Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited［J］. J Eur Acad Dermatol Venereol, 2017,31 Suppl 2:5⁃7. doi: 10.1111/jdv.14151.
［8］	Xu G, Fang J, Xu J, et al. Expression and significance of mammalian target of rapamycin in cutaneous squamous cell carcinoma and precancerous lesions［J］. Bioengineered, 2021,12（2）:9930⁃9938. doi: 10.1080/21655979.2021.1984719.
［9］	Weber P, Sinz C, Rinner C, et al. Perilesional sun damage as a diagnostic clue for pigmented actinic keratosis and Bowen′s disease［J］. J Eur Acad Dermatol Venereol, 2021,35（10）:2022⁃2026. doi: 10.1111/jdv.17464.
［10］	Rongioletti F. Actinic keratoses: what classification is useful to predict the risk of progression? Pros and cons［J］. J Eur Acad Dermatol Venereol, 2019,33（6）:983⁃984. doi: 10.1111/jdv.15649.
［11］	Papageorgiou C, Lallas A, Manoli SM, et al. Evaluation of dermatoscopic criteria for early detection of squamous cell carcinoma arising on an actinic keratosis［J］. J Am Acad Dermatol, 2022,86（4）:791⁃796. doi: 10.1016/j.jaad.2021.03.111.
［12］	Peppelman M, Nguyen KP, Hoogedoorn L, et al. Reflectance confocal microscopy: non⁃invasive distinction between actinic keratosis and squamous cell carcinoma［J］. J Eur Acad Dermatol Venereol, 2015,29（7）:1302⁃1309. doi: 10.1111/jdv.12806.
［13］	Zhu AQ, Wang LF, Li XL, et al. High⁃frequency ultrasound in the diagnosis of the spectrum of cutaneous squamous cell carcinoma: noninvasively distinguishing actinic keratosis, Bowen′s disease, and invasive squamous cell carcinoma［J］. Skin Res Technol, 2021,27（5）:831⁃840. doi: 10.1111/srt.13028.
［14］	Sanchez⁃Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas［J］. Cell, 2018,173（2）:321⁃337.e10. doi: 10.1016/j.cell.2018.03.035.
［15］	He S, Sharpless NE. Senescence in health and disease［J］. Cell, 2017,169（6）:1000⁃1011. doi: 10.1016/j.cell.2017.05.015.
［16］	Hodges A, Smoller BR. Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin［J］. Mod Pathol, 2002,15（11）:1121⁃1125. doi: 10.1097/01.MP.0000032536.48264.D1.
［17］	牛蕊仙, 徐丹, 何黎. 光线性角化病向鳞状细胞癌转化的分子机制研究进展［J］. 中华皮肤科杂志, 2016,49（2）:144⁃146. doi:10.3760/cma.j.issn.0412⁃4030.2016.02.021.
［18］	Salama ME, Mahmood MN, Qureshi HS, et al. p16INK4a expression in actinic keratosis and Bowen′s disease［J］. Br J Dermatol, 2003,149（5）:1006⁃1012. doi: 10.1111/j.1365⁃2133. 2003.05654.x.
［19］	Bagazgoitia L, Cuevas J, Juarranz A. Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen′s disease［J］. J Eur Acad Dermatol Venereol, 2010,24（2）:228⁃230. doi: 10.1111/j.1468⁃3083.2009.03337.x.
［20］	Azazmeh N, Assouline B, Winter E, et al. Chronic expression of p16INK4a in the epidermis induces Wnt⁃mediated hyperplasia and promotes tumor initiation［J］. Nat Commun, 2020,11（1）:2711. doi: 10.1038/s41467⁃020⁃16475⁃3.
［21］	Harvey NT, Leecy T, Wood BA. Immunohistochemical staining for p16 is a useful adjunctive test in the diagnosis of Bowen′s disease［J］. Pathology, 2013,45（4）:402⁃407. doi: 10.1097/PAT. 0b013e328360c064.
［22］	Genders RE, Beck S, Bouwes Bavinck JN, et al. p16 immunostaining in keratinocytic neoplasia in organ transplant recipients: Bowen′s disease shows a characteristic pattern［J］. J Cutan Pathol, 2017,44（1）:28⁃33. doi: 10.1111/cup.12840.
［23］	Nasiri S, Azhari V, Bidari⁃Zerehpoosh F, et al. The diagnostic value of p63, p16, and p53 immunohistochemistry in distingui⁃shing seborrheic keratosis, actinic keratosis, and Bowen′s disease ［J］. Dermatol Ther, 2021,34（2）:e14817. doi: 10.1111/dth.14817.
［24］	Matsushima N, Miyashita H, Kretsinger RH. Sequence features, structure, ligand interaction, and diseases in small leucine rich repeat proteoglycans［J］. J Cell Commun Signal, 2021,15（4）:519⁃531. doi: 10.1007/s12079⁃021⁃00616⁃4.
［25］	Giatagana EM, Berdiaki A, Tsatsakis A, et al. Lumican in carcinogenesis⁃revisited［J］. Biomolecules, 2021,11（9）:1319. doi: 10.3390/biom11091319.
［26］	Takayama R, Ishiwata T, Ansai S, et al. Lumican as a novel marker for differential diagnosis of Bowen disease and actinic keratosis［J］. Am J Dermatopathol, 2013,35（8）:827⁃832. doi: 10.1097/DAD.0b013e31827c7f31.
［27］	Wu J, Liu T, Rios Z, et al. Heat shock proteins and cancer［J］. Trends Pharmacol Sci, 2017,38（3）:226⁃256. doi: 10.1016/j.tips. 2016.11.009.
［28］	Rosenzweig R, Nillegoda NB, Mayer MP, et al. The Hsp70 chaperone network［J］. Nat Rev Mol Cell Biol, 2019,20（11）:665⁃680. doi: 10.1038/s41580⁃019⁃0133⁃3.
［29］	Sherman MY, Gabai VL. Hsp70 in cancer: back to the future［J］. Oncogene, 2015,34（32）:4153⁃4161. doi: 10.1038/onc.2014.349.
［30］	樊欣, 彭仁. 热休克蛋白70: 生物学功能与作用机制研究进展［J］. 生命科学, 2019,31（3）:270⁃278. doi: 10.13376/j.cbls/2019 039.
［31］	Fernández⁃Guarino M, Zamorano León JJ, López Farré AJ, et al. Cytoplasmic increase in Hsp70 protein: a potential new biomarker of early infiltration of cutaneous squamous cell carcinoma arising from actinic keratosis［J］. Cancers（Basel）, 2020,12（5）:1151. doi: 10.3390/cancers12051151.
［32］	Neto PD, Alchorne M, Michalany N, et al. Reduced p53 staining in actinic keratosis is associated with squamous cell carcinoma: a preliminary study［J］. Indian J Dermatol, 2013,58（4）:325. doi: 10.4103/0019⁃5154.113935.
［33］	Nindl I, Gottschling M, Krawtchenko N, et al. Low prevalence of p53, p16（INK4a） and Ha⁃ras tumour⁃specific mutations in low⁃graded actinic keratosis［J］. Br J Dermatol, 2007,156（Suppl 3）:34⁃39. doi: 10.1111/j.1365⁃2133.2007.07857.x.
［34］	Bakshi A, Shafi R, Nelson J, et al. The clinical course of actinic keratosis correlates with underlying molecular mechanisms［J］. Br J Dermatol, 2020,182（4）:995⁃1002. doi: 10.1111/bjd.18338.
［35］	Heerfordt IM, Nissen CV, Poulsen T, et al. Thickness of actinic keratosis does not predict dysplasia severity or p53 expression［J］. Sci Rep, 2016,6:33952. doi: 10.1038/srep33952.
［36］	Osanai M, Takasawa A, Murata M, et al. Claudins in cancer: bench to bedside［J］. Pflugers Arch, 2017,469（1）:55⁃67. doi: 10.1007/s00424⁃016⁃1877⁃7.
［37］	Bhat AA, Syed N, Therachiyil L, et al. Claudin⁃1, a double⁃edged sword in cancer［J］. Int J Mol Sci, 2020,21（2）:569. doi: 10.3390/ijms21020569.
［38］	Hintsala HR, Siponen M, Haapasaari KM, et al. Claudins 1, 2, 3, 4, 5 and 7 in solar keratosis and squamocellular carcinoma of the skin［J］. Int J Clin Exp Pathol, 2013,6（12）:2855⁃2863.
［39］	Lee JS, Park HS, Yoon HS, et al. Claudin⁃1 expression decreases with increasing pathological grade in actinic keratosis and may be a marker of high⁃risk actinic keratosis［J］. Clin Exp Dermatol, 2019,44（5）:483⁃490. doi: 10.1111/ced.13810.
［40］	徐丹, 刘彤云, 袁瑞红, 等. 紫外线对光化性角化病和正常皮肤p53、基质金属蛋白酶2、9表达的影响［J］. 中华皮肤科杂志, 2013,46（2）:113⁃116. doi: 10.3760/cma.j.issn.0412⁃4030. 2013.02.012.
［41］	Wang H, Li H, Yan Q, et al. Serum matrix metalloproteinase⁃13 as a diagnostic biomarker for cutaneous squamous cell carcinoma［J］. BMC Cancer, 2021,21（1）:816. doi: 10.1186/s12885⁃021⁃08566⁃1.
［42］	张子玲, 张亚楠, 张艳丽, 等. EZH2的表观遗传调控在肿瘤发生中的研究进展［J］. 国际遗传学杂志, 2022,45（1）:44⁃49. doi:10.3760/cma.j.cn231536⁃20210810⁃00102.
［43］	Xie Q, Wang H, Heilman ER, et al. Increased expression of enhancer of Zeste Homolog 2（EZH2） differentiates squamous cell carcinoma from normal skin and actinic keratosis［J］. Eur J Dermatol, 2014,24（1）:41⁃45. doi: 10.1684/ejd.2013.2219.
［44］	Persechino F, Ranieri D, Guttieri L, et al. Expression profile of fibroblast growth factor receptors, keratinocyte differentiation markers, and epithelial mesenchymal transition⁃related genes in actinic keratosis: a possible predictive factor for malignant progression?［J］. Biology（Basel）, 2021,10（4）:331. doi: 10. 3390/biology10040331.
［45］	Bacchetti T, Ferretti G, Sahebkar A. The role of paraoxonase in cancer［J］. Semin Cancer Biol, 2019,56:72⁃86. doi: 10.1016/j.semcancer.2017.11.013.
［46］	Sartini D, Campagna R, Lucarini G, et al. Differential immunohistochemical expression of paraoxonase⁃2 in actinic keratosis and squamous cell carcinoma［J］. Hum Cell, 2021,34（6）:1929⁃1931. doi: 10.1007/s13577⁃021⁃00581⁃5.
［47］	Buechner SA, Resink TJ. T⁃cadherin expression in actinic keratosis transforming to invasive squamous cell carcinoma［J］. Dermatopathology（Basel）, 2019,6（1）:12⁃19. doi: 10.1159/000 495609.

[1]	陈玉沙汪盛. 遗传性光敏感性皮肤病[J]. 中华皮肤科杂志, 2024, 57(3): 279-282.
[2]	郝丹王怡怡肖月闫薇李薇. [开放获取] 特殊部位银屑病系统治疗临床研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230190-e20230190.
[3]	洪永镇王倩梁俊琴. 二代测序技术在非遗传性皮肤病领域中的运用[J]. 中华皮肤科杂志, 2024, 0(3): 20220436-e20220436.
[4]	王煜坤刘洁. 深度学习在非肿瘤性皮肤病中的应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220660-e20220660.
[5]	葛新红马迎东焦亚宁刘玲玲周镁紫薇李博文. 532 nm皮秒激光治疗面部早期脂溢性角化病的疗效和安全性分析[J]. 中华皮肤科杂志, 2024, 0(2): 20230061-e20230061.
[6]	丁高中刘梦茜马伟李姗姗孙澜陈朝潮. 甲母质细胞癌1例[J]. 中华皮肤科杂志, 2024, 57(2): 165-167.
[7]	中国中西医结合学会皮肤性病专业委员会皮肤肿瘤学组中国抗癌协会黑色素瘤专业委员会. [开放获取] 人干扰素α1b治疗黑色素瘤专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(1): 1-7.
[8]	岳超段梦莹王涛章满玉戴叶芹彭建中宋秀祖. 上睑眼轮匝肌岛状皮瓣修复眼睑及眶周皮肤肿瘤切除后继发缺损28例回顾性分析[J]. 中华皮肤科杂志, 2023, 56(9): 862-865.
[9]	董栋刘天一. 细胞代谢与皮肤恶性黑素瘤转移的研究进展[J]. 中华皮肤科杂志, 2023, 56(9): 878-881.
[10]	邵依王雷刘芳. 蕈样肉芽肿伴大细胞转化和原发性皮肤间变性大细胞淋巴瘤临床病理比较分析[J]. 中华皮肤科杂志, 2023, 56(9): 853-857.
[11]	张俐施健葛鑫刘念念陈赛张冬梅缪旭. Brahma相关基因1与激活转录因子2相互作用对皮肤鳞状细胞癌细胞增殖、迁移和侵袭能力的影响[J]. 中华皮肤科杂志, 2023, 56(8): 724-736.
[12]	宋德宇王嘉玥耿佳邹美熔李仲桃陈玉沙汪盛. GJB2基因p.N54H突变致经典型Vohwinkel综合征1例[J]. 中华皮肤科杂志, 2023, 56(7): 669-672.
[13]	《蕈样肉芽肿治疗中国专家共识》编写专家组. [开放获取] 蕈样肉芽肿治疗中国专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(5): 402-409.
[14]	王媛王艺萌吴雯婷李婷婷王冠钰张春雷. 葡萄糖转运蛋白3在皮肤鳞状细胞癌中的表达及其对A431细胞增殖、侵袭及迁移的影响[J]. 中华皮肤科杂志, 2023, 56(5): 421-427.
[15]	张聪聪陈浩. Spitz样肿瘤的研究进展[J]. 中华皮肤科杂志, 2023, 56(5): 463-467.

光线性角化病恶性进展相关生物标志物的研究进展

Biomarkers associated with malignant progression of actinic keratosis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 47

相关文章 15

Metrics

本文评价

推荐阅读 10